These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 30706249

  • 1. Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy.
    Amini E, Ahmadi N, Clifford TG, Hugen CM, Bazargani ST, Cai J, Miranda G, Sherrod AE, Daneshmand S, Djaladat H.
    Int Urol Nephrol; 2019 Mar; 51(3):435-441. PubMed ID: 30706249
    [Abstract] [Full Text] [Related]

  • 2. Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy.
    Chen J, Miranda G, Cai J, Daneshmand S, Djaladat H.
    Scand J Urol; 2019 Mar; 53(2-3):123-128. PubMed ID: 31081431
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
    Weight CJ, Garcia JA, Hansel DE, Fergany AF, Campbell SC, Gong MC, Jones JS, Klein EA, Dreicer R, Stephenson AJ.
    Cancer; 2009 Feb 15; 115(4):792-9. PubMed ID: 19127557
    [Abstract] [Full Text] [Related]

  • 6. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
    Iwasaki K, Obara W, Kato Y, Takata R, Tanji S, Fujioka T.
    Jpn J Clin Oncol; 2013 Feb 15; 43(2):193-9. PubMed ID: 23275643
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
    Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin R, Lieskovsky G, Schuckman A, Cai J, Miranda G, Skinner EC.
    Urol Oncol; 2013 Nov 15; 31(8):1737-43. PubMed ID: 23141776
    [Abstract] [Full Text] [Related]

  • 9. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC.
    Eur Urol; 2015 Feb 15; 67(2):241-9. PubMed ID: 25257030
    [Abstract] [Full Text] [Related]

  • 10. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.
    Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC.
    World J Urol; 2019 Jan 15; 37(1):165-172. PubMed ID: 29882105
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Krabbe LM, Westerman ME, Margulis V, Raj GV, Sagalowsky AI, Courtney K, Arriaga Y, Lotan Y.
    Can J Urol; 2015 Aug 15; 22(4):7865-75. PubMed ID: 26267024
    [Abstract] [Full Text] [Related]

  • 13. Outcome of urinary bladder cancer after combined therapies.
    Anghel RM, Gales LN, Trifanescu OG.
    J Med Life; 2016 Aug 15; 9(2):153-9. PubMed ID: 27453746
    [Abstract] [Full Text] [Related]

  • 14. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
    Kitagawa Y, Izumi K, Miwa S, Kadono Y, Konaka H, Mizokami A, Namiki M.
    Anticancer Res; 2013 Oct 15; 33(10):4497-503. PubMed ID: 24123021
    [Abstract] [Full Text] [Related]

  • 15. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
    Cancer; 2015 Aug 01; 121(15):2586-93. PubMed ID: 25872978
    [Abstract] [Full Text] [Related]

  • 16. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
    Tachibana I, Bandali E, Calaway AC, Krishnan N, Cheng L, Adra N, Kaimakliotis HZ.
    Urol Oncol; 2020 Nov 01; 38(11):850.e1-850.e7. PubMed ID: 32693973
    [Abstract] [Full Text] [Related]

  • 17. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
    North S, El-Gehani F, Santos C, Ghosh S, Lai R, Cass CE, Mackey JR.
    J Urol; 2014 Jan 01; 191(1):35-9. PubMed ID: 23851183
    [Abstract] [Full Text] [Related]

  • 18. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
    Murasawa H, Koie T, Ohyama C, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Iwabuchi I, Ogasawara M, Kawaguchi T.
    Int J Clin Oncol; 2017 Feb 01; 22(1):159-165. PubMed ID: 27534866
    [Abstract] [Full Text] [Related]

  • 19. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
    Bhindi B, Frank I, Mason RJ, Tarrell RF, Thapa P, Cheville JC, Costello BA, Pagliaro LC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA.
    Eur Urol; 2017 Nov 01; 72(5):660-664. PubMed ID: 28545841
    [Abstract] [Full Text] [Related]

  • 20. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
    Dash A, Pettus JA, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF.
    Cancer; 2008 Nov 01; 113(9):2471-7. PubMed ID: 18823036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.